WGU D116 Advanced Pharmacology OA Exam Prep
Document | 2026/2027 Edition | 150 Verified Questions
WGU D116 Advanced Pharmacology OA Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide contains 150 verified questions with detailed rationales
for the WGU D116 Advanced Pharmacology Objective Assessment. Designed for the 2026/2027
academic year, it covers all major pharmacology topics including pharmacokinetics,
pharmacodynamics, drug classifications, and therapeutic management. Each question is accompanied
by evidence-based rationales and distractor explanations to reinforce learning. This resource is
essential for nursing and healthcare students seeking a thorough understanding of advanced
pharmacological principles.
Key Features:
Pharmacokinetics and Pharmacodynamics
Drug Classifications and Mechanisms of Action
Therapeutic Drug Monitoring and Adverse Effects
Special Populations: Pediatrics, Geriatrics, Pregnancy
Antimicrobial Therapy and Resistance
Cardiovascular, Endocrine, and CNS Pharmacology
Updates for 2026:
- Updated to reflect 2026/2027 WGU D116 curriculum changes
- Incorporated latest FDA drug approvals and safety alerts
- Revised rationales based on current clinical practice guidelines
- Added new questions on biologic therapies and targeted agents
- Enhanced distractor explanations for improved critical thinking
Abstract:
The WGU D116 Advanced Pharmacology OA Exam Prep Document for the 2026/2027 academic year provides a
rigorous review of advanced pharmacological concepts essential for nursing practice. This resource includes 150
verified questions with detailed rationales, covering pharmacokinetics, pharmacodynamics, drug classifications,
and therapeutic applications across major body systems. Special emphasis is placed on evidence-based
prescribing, adverse drug reactions, drug interactions, and patient-specific considerations. Each question is
designed to mirror the format and difficulty of the actual OA, with rationales that explain correct answers and
analyze common misconceptions. The document also addresses recent updates in pharmacotherapy, including new
drug approvals and guideline changes. By systematically working through these questions, students can identify
knowledge gaps and reinforce key principles, ensuring readiness for the exam and clinical application. This guide
is an indispensable tool for achieving a high score on the WGU D116 Advanced Pharmacology OA.
Keywords:
WGU D116, Advanced Pharmacology, OA Exam, Pharmacokinetics, Pharmacodynamics, Drug Classifications,
Therapeutic Drug Monitoring, Evidence-Based Prescribing
Answer Format:
Each question is followed by a detailed rationale that explains the correct answer and why the other options are
incorrect. Distractor explanations highlight common errors and misconceptions, reinforcing key pharmacological
principles. Answers are presented in a clear, concise format to facilitate efficient study and self-assessment.
Compliance Checklist:
Page 1
, Aligned with WGU D116 Advanced Pharmacology OA blueprint
Updated for 2026/2027 academic year guidelines
Includes 150 verified questions with rationales
Covers all major content areas with appropriate weighting
Provides evidence-based explanations and references
Designed for self-paced study and exam readiness
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Drug Classifications and 31-60 Autonomic, Cardiovascular, Endocrine, 20%
Mechanisms CNS, Antimicrobials
Therapeutic Drug Monitoring 61-90 Drug Interactions, Toxicity, Monitoring 20%
and Adverse Effects Parameters, Adverse Reactions
Special Populations 91-110 Pediatrics, Geriatrics, Pregnancy, Lactation, 13%
Renal/Hepatic Impairment
Antimicrobial Therapy 111-130 Antibiotics, Antivirals, Antifungals, 13%
Resistance Mechanisms, Stewardship
Clinical Application and Case 131-150 Prescribing Scenarios, Patient Education, 14%
Studies Evidence-Based Guidelines
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease stage 3b (eGFR 35 mL/min/1.73m²) requires
initiation of an SGLT2 inhibitor. Which of the following considerations is most critical regarding the choice
and monitoring of this therapy?
A. SGLT2 inhibitors are contraindicated when eGFR is below 45 mL/min/1.73m², so an alternative class must
be selected.
B. Dapagliflozin may be initiated with close monitoring of renal function and volume status, as it retains
efficacy at lower eGFR.
C. Empagliflozin is preferred because it has proven cardiovascular benefit regardless of baseline eGFR.
D. All SGLT2 inhibitors require dose adjustment for renal impairment, and canagliflozin is safest in this
setting.
Correct Answer: B. Dapagliflozin may be initiated with close monitoring of renal function and volume status,
as it retains efficacy at lower eGFR.
Rationale: Recent guidelines from the ADA and KDIGO support the use of SGLT2 inhibitors like dapagliflozin in
patients with eGFR as low as 25 mL/min/1.73m² for cardiorenal protection, though glucose-lowering efficacy
diminishes. Option A is outdated; many SGLT2 inhibitors are now approved down to eGFR 25. Option C is
incorrect because empagliflozin's cardiovascular benefit is established but not exclusive, and its renal benefit also
requires eGFR 30. Option D is false; canagliflozin carries higher amputation risk, and dose adjustment varies by
agent.
Why Wrong:
A - This is an outdated contraindication; current guidelines allow SGLT2 inhibitors down to eGFR 25-30
mL/min/1.73m².
C - Empagliflozin has cardiovascular benefit, but it is not the only choice; dapagliflozin also has proven
benefit and can be used at lower eGFR.
D - Canagliflozin is not the safest; it has increased risk of lower limb amputations and fractures; no single
agent is uniformly safest.
Reference: American Diabetes Association. (2026). Standards of Medical Care in Diabetes-2026. Diabetes Care,
49(Suppl 1), S112-S127.
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.8. The patient has no bleeding. The
most appropriate management strategy is:
A. Administer 10 mg oral vitamin K and resume warfarin at a reduced dose once INR is therapeutic.
B. Hold warfarin, administer 1-2 mg oral vitamin K, and recheck INR in 24 hours.
C. Administer 5 mg intravenous vitamin K and 2 units of fresh frozen plasma.
D. Hold warfarin for 1-2 days and recheck INR; no vitamin K is needed as the patient is not bleeding.
Correct Answer: B. Hold warfarin, administer 1-2 mg oral vitamin K, and recheck INR in 24 hours.
Rationale: For a non-bleeding patient with INR >4.5 but <10, guidelines recommend holding warfarin and giving
low-dose oral vitamin K (1-2 mg) to accelerate return to therapeutic range. Option A gives too high a dose (10 mg)
which may cause resistance to warfarin for over a week. Option C is for major bleeding. Option D is insufficient as
INR >5 significantly increases bleeding risk, and guidelines favor low-dose vitamin K to shorten the time of
elevated INR.
Why Wrong:
A - 10 mg oral vitamin K is too high; it may cause overcorrection and warfarin resistance for days.
C - IV vitamin K and FFP are indicated for major bleeding, not for asymptomatic elevated INR.
D - Holding warfarin alone may take several days for INR to fall, exposing the patient to prolonged bleeding
risk.
Reference: Douketis, J.D., et al. (2026). Anticoagulation management: ASH guideline. Blood Advances, 10(2),
123-135.
Page 3
, Q3. A patient with severe depression has failed two adequate trials of SSRIs and one trial of venlafaxine. The
patient also has chronic neuropathic pain. Which augmentation strategy is most appropriate?
A. Add bupropion to the current SSRI regimen.
B. Switch to duloxetine monotherapy.
C. Add aripiprazole to the current antidepressant.
D. Add lithium to the current antidepressant.
Correct Answer: B. Switch to duloxetine monotherapy.
Rationale: Duloxetine is an SNRI that is FDA-approved for both major depressive disorder and neuropathic pain (diabetic
peripheral neuropathy, fibromyalgia). Given the patient's dual needs, switching to duloxetine addresses both conditions with a
single agent, which is efficient. Bupropion (A) is effective for depression but does not treat neuropathic pain. Aripiprazole (C)
and lithium (D) are evidence-based augmentations for treatment-resistant depression but do not address pain.
Why Wrong:
A - Bupropion is not effective for neuropathic pain and may even worsen anxiety.
C - Aripiprazole is a valid augmentation for depression but does not treat neuropathic pain.
D - Lithium is effective for augmentation but has no analgesic properties and requires monitoring.
Reference: American Psychiatric Association. (2026). Practice Guideline for the Treatment of Patients with Major Depressive
Disorder, 4th ed. APA Publishing.
Q4. Which of the following best describes the mechanism by which metformin reduces hepatic glucose
production?
A. Activation of AMPK leading to inhibition of gluconeogenic enzymes and reduced gluconeogenesis.
B. Inhibition of mitochondrial complex I resulting in decreased ATP and activation of AMPK, which
suppresses gluconeogenesis.
C. Direct binding to and inhibition of the glucose-6-phosphatase enzyme.
D. Increased insulin secretion from pancreatic beta cells via closure of K-ATP channels.
Correct Answer: B. Inhibition of mitochondrial complex I resulting in decreased ATP and activation of
AMPK, which suppresses gluconeogenesis.
Rationale: Metformin's primary mechanism is inhibition of mitochondrial complex I, which reduces ATP
production and increases AMP/ATP ratio, activating AMPK. AMPK then phosphorylates and inhibits key
gluconeogenic enzymes (e.g., PEPCK, G6Pase). While AMPK activation is involved, the direct trigger is
mitochondrial inhibition. Option A is incomplete as it omits the upstream mitochondrial effect. Option C is
incorrect; metformin does not directly bind G6Pase. Option D describes sulfonylureas, not metformin.
Why Wrong:
A - AMPK activation is a downstream effect, but the primary mechanism is mitochondrial complex I
inhibition.
C - Metformin does not directly inhibit glucose-6-phosphatase; it acts upstream via AMPK.
D - Metformin does not stimulate insulin secretion; that is the mechanism of sulfonylureas.
Reference: LaMoia, T.E., & Shulman, G.I. (2021). Cellular and molecular mechanisms of metformin action.
Endocrine Reviews, 42(1), 77-96.
Q5. A patient with a history of opioid use disorder is being started on buprenorphine/naloxone for
maintenance therapy. Which statement accurately describes the rationale for including naloxone?
A. Naloxone enhances the analgesic effect of buprenorphine by preventing its metabolism.
B. Naloxone is included to prevent respiratory depression by partially antagonizing buprenorphine at the mu
receptor.
C. Naloxone is added to deter intravenous abuse; it has negligible oral bioavailability but if injected, it
precipitates withdrawal.
D. Naloxone increases the half-life of buprenorphine by competing for hepatic metabolism.
Page 4
Document | 2026/2027 Edition | 150 Verified Questions
WGU D116 Advanced Pharmacology OA Exam 2026-2027 QUESTIONS AND ANSWERS
ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation guide contains 150 verified questions with detailed rationales
for the WGU D116 Advanced Pharmacology Objective Assessment. Designed for the 2026/2027
academic year, it covers all major pharmacology topics including pharmacokinetics,
pharmacodynamics, drug classifications, and therapeutic management. Each question is accompanied
by evidence-based rationales and distractor explanations to reinforce learning. This resource is
essential for nursing and healthcare students seeking a thorough understanding of advanced
pharmacological principles.
Key Features:
Pharmacokinetics and Pharmacodynamics
Drug Classifications and Mechanisms of Action
Therapeutic Drug Monitoring and Adverse Effects
Special Populations: Pediatrics, Geriatrics, Pregnancy
Antimicrobial Therapy and Resistance
Cardiovascular, Endocrine, and CNS Pharmacology
Updates for 2026:
- Updated to reflect 2026/2027 WGU D116 curriculum changes
- Incorporated latest FDA drug approvals and safety alerts
- Revised rationales based on current clinical practice guidelines
- Added new questions on biologic therapies and targeted agents
- Enhanced distractor explanations for improved critical thinking
Abstract:
The WGU D116 Advanced Pharmacology OA Exam Prep Document for the 2026/2027 academic year provides a
rigorous review of advanced pharmacological concepts essential for nursing practice. This resource includes 150
verified questions with detailed rationales, covering pharmacokinetics, pharmacodynamics, drug classifications,
and therapeutic applications across major body systems. Special emphasis is placed on evidence-based
prescribing, adverse drug reactions, drug interactions, and patient-specific considerations. Each question is
designed to mirror the format and difficulty of the actual OA, with rationales that explain correct answers and
analyze common misconceptions. The document also addresses recent updates in pharmacotherapy, including new
drug approvals and guideline changes. By systematically working through these questions, students can identify
knowledge gaps and reinforce key principles, ensuring readiness for the exam and clinical application. This guide
is an indispensable tool for achieving a high score on the WGU D116 Advanced Pharmacology OA.
Keywords:
WGU D116, Advanced Pharmacology, OA Exam, Pharmacokinetics, Pharmacodynamics, Drug Classifications,
Therapeutic Drug Monitoring, Evidence-Based Prescribing
Answer Format:
Each question is followed by a detailed rationale that explains the correct answer and why the other options are
incorrect. Distractor explanations highlight common errors and misconceptions, reinforcing key pharmacological
principles. Answers are presented in a clear, concise format to facilitate efficient study and self-assessment.
Compliance Checklist:
Page 1
, Aligned with WGU D116 Advanced Pharmacology OA blueprint
Updated for 2026/2027 academic year guidelines
Includes 150 verified questions with rationales
Covers all major content areas with appropriate weighting
Provides evidence-based explanations and references
Designed for self-paced study and exam readiness
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 20%
Pharmacodynamics Excretion, Receptor Theory, Dose-Response
Drug Classifications and 31-60 Autonomic, Cardiovascular, Endocrine, 20%
Mechanisms CNS, Antimicrobials
Therapeutic Drug Monitoring 61-90 Drug Interactions, Toxicity, Monitoring 20%
and Adverse Effects Parameters, Adverse Reactions
Special Populations 91-110 Pediatrics, Geriatrics, Pregnancy, Lactation, 13%
Renal/Hepatic Impairment
Antimicrobial Therapy 111-130 Antibiotics, Antivirals, Antifungals, 13%
Resistance Mechanisms, Stewardship
Clinical Application and Case 131-150 Prescribing Scenarios, Patient Education, 14%
Studies Evidence-Based Guidelines
Page 2
,Q1. A patient with type 2 diabetes and chronic kidney disease stage 3b (eGFR 35 mL/min/1.73m²) requires
initiation of an SGLT2 inhibitor. Which of the following considerations is most critical regarding the choice
and monitoring of this therapy?
A. SGLT2 inhibitors are contraindicated when eGFR is below 45 mL/min/1.73m², so an alternative class must
be selected.
B. Dapagliflozin may be initiated with close monitoring of renal function and volume status, as it retains
efficacy at lower eGFR.
C. Empagliflozin is preferred because it has proven cardiovascular benefit regardless of baseline eGFR.
D. All SGLT2 inhibitors require dose adjustment for renal impairment, and canagliflozin is safest in this
setting.
Correct Answer: B. Dapagliflozin may be initiated with close monitoring of renal function and volume status,
as it retains efficacy at lower eGFR.
Rationale: Recent guidelines from the ADA and KDIGO support the use of SGLT2 inhibitors like dapagliflozin in
patients with eGFR as low as 25 mL/min/1.73m² for cardiorenal protection, though glucose-lowering efficacy
diminishes. Option A is outdated; many SGLT2 inhibitors are now approved down to eGFR 25. Option C is
incorrect because empagliflozin's cardiovascular benefit is established but not exclusive, and its renal benefit also
requires eGFR 30. Option D is false; canagliflozin carries higher amputation risk, and dose adjustment varies by
agent.
Why Wrong:
A - This is an outdated contraindication; current guidelines allow SGLT2 inhibitors down to eGFR 25-30
mL/min/1.73m².
C - Empagliflozin has cardiovascular benefit, but it is not the only choice; dapagliflozin also has proven
benefit and can be used at lower eGFR.
D - Canagliflozin is not the safest; it has increased risk of lower limb amputations and fractures; no single
agent is uniformly safest.
Reference: American Diabetes Association. (2026). Standards of Medical Care in Diabetes-2026. Diabetes Care,
49(Suppl 1), S112-S127.
Q2. A patient on warfarin for atrial fibrillation presents with an INR of 5.8. The patient has no bleeding. The
most appropriate management strategy is:
A. Administer 10 mg oral vitamin K and resume warfarin at a reduced dose once INR is therapeutic.
B. Hold warfarin, administer 1-2 mg oral vitamin K, and recheck INR in 24 hours.
C. Administer 5 mg intravenous vitamin K and 2 units of fresh frozen plasma.
D. Hold warfarin for 1-2 days and recheck INR; no vitamin K is needed as the patient is not bleeding.
Correct Answer: B. Hold warfarin, administer 1-2 mg oral vitamin K, and recheck INR in 24 hours.
Rationale: For a non-bleeding patient with INR >4.5 but <10, guidelines recommend holding warfarin and giving
low-dose oral vitamin K (1-2 mg) to accelerate return to therapeutic range. Option A gives too high a dose (10 mg)
which may cause resistance to warfarin for over a week. Option C is for major bleeding. Option D is insufficient as
INR >5 significantly increases bleeding risk, and guidelines favor low-dose vitamin K to shorten the time of
elevated INR.
Why Wrong:
A - 10 mg oral vitamin K is too high; it may cause overcorrection and warfarin resistance for days.
C - IV vitamin K and FFP are indicated for major bleeding, not for asymptomatic elevated INR.
D - Holding warfarin alone may take several days for INR to fall, exposing the patient to prolonged bleeding
risk.
Reference: Douketis, J.D., et al. (2026). Anticoagulation management: ASH guideline. Blood Advances, 10(2),
123-135.
Page 3
, Q3. A patient with severe depression has failed two adequate trials of SSRIs and one trial of venlafaxine. The
patient also has chronic neuropathic pain. Which augmentation strategy is most appropriate?
A. Add bupropion to the current SSRI regimen.
B. Switch to duloxetine monotherapy.
C. Add aripiprazole to the current antidepressant.
D. Add lithium to the current antidepressant.
Correct Answer: B. Switch to duloxetine monotherapy.
Rationale: Duloxetine is an SNRI that is FDA-approved for both major depressive disorder and neuropathic pain (diabetic
peripheral neuropathy, fibromyalgia). Given the patient's dual needs, switching to duloxetine addresses both conditions with a
single agent, which is efficient. Bupropion (A) is effective for depression but does not treat neuropathic pain. Aripiprazole (C)
and lithium (D) are evidence-based augmentations for treatment-resistant depression but do not address pain.
Why Wrong:
A - Bupropion is not effective for neuropathic pain and may even worsen anxiety.
C - Aripiprazole is a valid augmentation for depression but does not treat neuropathic pain.
D - Lithium is effective for augmentation but has no analgesic properties and requires monitoring.
Reference: American Psychiatric Association. (2026). Practice Guideline for the Treatment of Patients with Major Depressive
Disorder, 4th ed. APA Publishing.
Q4. Which of the following best describes the mechanism by which metformin reduces hepatic glucose
production?
A. Activation of AMPK leading to inhibition of gluconeogenic enzymes and reduced gluconeogenesis.
B. Inhibition of mitochondrial complex I resulting in decreased ATP and activation of AMPK, which
suppresses gluconeogenesis.
C. Direct binding to and inhibition of the glucose-6-phosphatase enzyme.
D. Increased insulin secretion from pancreatic beta cells via closure of K-ATP channels.
Correct Answer: B. Inhibition of mitochondrial complex I resulting in decreased ATP and activation of
AMPK, which suppresses gluconeogenesis.
Rationale: Metformin's primary mechanism is inhibition of mitochondrial complex I, which reduces ATP
production and increases AMP/ATP ratio, activating AMPK. AMPK then phosphorylates and inhibits key
gluconeogenic enzymes (e.g., PEPCK, G6Pase). While AMPK activation is involved, the direct trigger is
mitochondrial inhibition. Option A is incomplete as it omits the upstream mitochondrial effect. Option C is
incorrect; metformin does not directly bind G6Pase. Option D describes sulfonylureas, not metformin.
Why Wrong:
A - AMPK activation is a downstream effect, but the primary mechanism is mitochondrial complex I
inhibition.
C - Metformin does not directly inhibit glucose-6-phosphatase; it acts upstream via AMPK.
D - Metformin does not stimulate insulin secretion; that is the mechanism of sulfonylureas.
Reference: LaMoia, T.E., & Shulman, G.I. (2021). Cellular and molecular mechanisms of metformin action.
Endocrine Reviews, 42(1), 77-96.
Q5. A patient with a history of opioid use disorder is being started on buprenorphine/naloxone for
maintenance therapy. Which statement accurately describes the rationale for including naloxone?
A. Naloxone enhances the analgesic effect of buprenorphine by preventing its metabolism.
B. Naloxone is included to prevent respiratory depression by partially antagonizing buprenorphine at the mu
receptor.
C. Naloxone is added to deter intravenous abuse; it has negligible oral bioavailability but if injected, it
precipitates withdrawal.
D. Naloxone increases the half-life of buprenorphine by competing for hepatic metabolism.
Page 4
